The Board of Directors of Sweden’s Arcam AB reports that it is initiating a process to explore and evaluate strategic alternatives regarding DiSanto Technology Inc. (DTI), to strengthen its focus and capabilities within both Additive Manufacturing and conventional manufacturing.
As part of this process, the company stated that it intends to consider a range of strategic and structural options, which may include, among other things, a restructuring, full or partial separation of DTI via a spin-off, sale, joint venture, strategic collaboration or other transaction.
The evaluation is part of Arcam’s continued efforts to allocate resources and capital to maximise the advancement of its offerings for its customers. Arcam stated that its objective is to strengthen DTI’s ability to serve as a contract manufacturing partner to orthopaedic customers seeking to combine the benefits of Additive Manufacturing with traditional manufacturing capabilities.
Arcam also stated that it has engaged Viant Capital, LLC as financial advisor to assist in the review of strategic alternatives for DTI.